Inequalities in the burden of non-communicable diseases across European countries: a systematic analysis of the Global Burden of Disease 2019 study.
DALY rate
European Economic Area
European Union
Global Burden of Disease
Health inequality
Non-communicable diseases
Journal
International journal for equity in health
ISSN: 1475-9276
Titre abrégé: Int J Equity Health
Pays: England
ID NLM: 101147692
Informations de publication
Date de publication:
28 07 2023
28 07 2023
Historique:
received:
17
05
2023
accepted:
10
07
2023
medline:
31
7
2023
pubmed:
29
7
2023
entrez:
28
7
2023
Statut:
epublish
Résumé
Although overall health status in the last decades improved, health inequalities due to non-communicable diseases (NCDs) persist between and within European countries. There is a lack of studies giving insights into health inequalities related to NCDs in the European Economic Area (EEA) countries. Therefore, the aim of the present study was to quantify health inequalities in age-standardized disability adjusted life years (DALY) rates for NCDs overall and 12 specific NCDs across 30 EEA countries between 1990 and 2019. Also, this study aimed to determine trends in health inequalities and to identify those NCDs where the inequalities were the highest. DALY rate ratios were calculated to determine and compare inequalities between the 30 EEA countries, by sex, and across time. Annual rate of change was used to determine the differences in DALY rate between 1990 and 2019 for males and females. The Gini Coefficient (GC) was used to measure the DALY rate inequalities across countries, and the Slope Index of Inequality (SII) to estimate the average absolute difference in DALY rate across countries. Between 1990 and 2019, there was an overall declining trend in DALY rate, with larger declines among females compared to males. Among EEA countries, in 2019 the highest NCD DALY rate for both sexes were observed for Bulgaria. For the whole period, the highest DALY rate ratios were identified for digestive diseases, diabetes and kidney diseases, substance use disorders, cardiovascular diseases (CVD), and chronic respiratory diseases - representing the highest inequality between countries. In 2019, the highest DALY rate ratio was found between Bulgaria and Iceland for males. GC and SII indicated that the highest inequalities were due to CVD for most of the study period - however, overall levels of inequality were low. The inequality in level 1 NCDs DALYs rate is relatively low among all the countries. CVDs, digestive diseases, diabetes and kidney diseases, substance use disorders, and chronic respiratory diseases are the NCDs that exhibit higher levels of inequality across countries in the EEA. This might be mitigated by applying tailored preventive measures and enabling healthcare access.
Sections du résumé
BACKGROUND
Although overall health status in the last decades improved, health inequalities due to non-communicable diseases (NCDs) persist between and within European countries. There is a lack of studies giving insights into health inequalities related to NCDs in the European Economic Area (EEA) countries. Therefore, the aim of the present study was to quantify health inequalities in age-standardized disability adjusted life years (DALY) rates for NCDs overall and 12 specific NCDs across 30 EEA countries between 1990 and 2019. Also, this study aimed to determine trends in health inequalities and to identify those NCDs where the inequalities were the highest.
METHODS
DALY rate ratios were calculated to determine and compare inequalities between the 30 EEA countries, by sex, and across time. Annual rate of change was used to determine the differences in DALY rate between 1990 and 2019 for males and females. The Gini Coefficient (GC) was used to measure the DALY rate inequalities across countries, and the Slope Index of Inequality (SII) to estimate the average absolute difference in DALY rate across countries.
RESULTS
Between 1990 and 2019, there was an overall declining trend in DALY rate, with larger declines among females compared to males. Among EEA countries, in 2019 the highest NCD DALY rate for both sexes were observed for Bulgaria. For the whole period, the highest DALY rate ratios were identified for digestive diseases, diabetes and kidney diseases, substance use disorders, cardiovascular diseases (CVD), and chronic respiratory diseases - representing the highest inequality between countries. In 2019, the highest DALY rate ratio was found between Bulgaria and Iceland for males. GC and SII indicated that the highest inequalities were due to CVD for most of the study period - however, overall levels of inequality were low.
CONCLUSIONS
The inequality in level 1 NCDs DALYs rate is relatively low among all the countries. CVDs, digestive diseases, diabetes and kidney diseases, substance use disorders, and chronic respiratory diseases are the NCDs that exhibit higher levels of inequality across countries in the EEA. This might be mitigated by applying tailored preventive measures and enabling healthcare access.
Identifiants
pubmed: 37507733
doi: 10.1186/s12939-023-01958-8
pii: 10.1186/s12939-023-01958-8
pmc: PMC10375608
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
140Informations de copyright
© 2023. The Author(s).
Références
Diabetes Res Clin Pract. 2021 Jul;177:108822
pubmed: 33872631
Front Public Health. 2022 Nov 23;10:1002265
pubmed: 36504978
PLoS Med. 2016 Feb 23;13(2):e1001963
pubmed: 26905063
Soc Sci Med. 2000 May;50(10):1385-401
pubmed: 10741575
Int J Behav Nutr Phys Act. 2012 Sep 19;9:116
pubmed: 22992350
Alcohol Alcohol. 2010 May-Jun;45(3):252-7
pubmed: 20406791
Health Policy Plan. 2016 Apr;31 Suppl 1:i98-109
pubmed: 26733720
Lancet Child Adolesc Health. 2022 Jun;6(6):367-383
pubmed: 35339209
Bull World Health Organ. 1994;72(3):495-509
pubmed: 8062404
Lancet. 2021 Dec 19;396(10267):2006-2017
pubmed: 33275908
Appetite. 2007 Jul;49(1):169-76
pubmed: 17368642
Proc Natl Acad Sci U S A. 2018 Jun 19;115(25):6440-6445
pubmed: 29866829
Eur J Public Health. 2021 Oct 26;31(5):958-967
pubmed: 34468766
Int J Public Health. 2020 Mar;65(2):175-186
pubmed: 32067062
Global Health. 2017 Dec 20;13(1):91
pubmed: 29262849
FASEB Bioadv. 2021 Apr 29;3(8):563-568
pubmed: 34377953
Eur J Popul. 2021 Oct 07;37(4-5):909-931
pubmed: 34786002
J Epidemiol Community Health. 2011 May;65(5):412-9
pubmed: 21172799
N Engl J Med. 2008 Jun 5;358(23):2468-81
pubmed: 18525043
BMC Public Health. 2012 Jun 22;12:474
pubmed: 22726343
Curr Epidemiol Rep. 2016 Mar;3(1):81-91
pubmed: 27239427
Lancet Reg Health West Pac. 2022 Apr;21:100377
pubmed: 35098183
Int J Equity Health. 2016 Sep 01;15(1):135
pubmed: 27586144
Perspect Public Health. 2021 May;141(3):158-176
pubmed: 32449467
Eur J Public Health. 2017 Feb 1;27(suppl_1):22-26
pubmed: 28355638
Eur J Public Health. 2019 Feb 1;29(1):105-110
pubmed: 30169634
JAMA Oncol. 2022 Mar 01;8(3):420-444
pubmed: 34967848
Aging Clin Exp Res. 2020 Jul;32(7):1189-1194
pubmed: 32458356
Sci Rep. 2020 Sep 8;10(1):14790
pubmed: 32901098
Tob Control. 2019 Jan;28(1):101-109
pubmed: 29472445
Lancet. 2018 May 19;391(10134):2036-2046
pubmed: 29627160
Lancet Neurol. 2018 Nov;17(11):939-953
pubmed: 30287051
Int J Health Serv. 2016;46(2):208-40
pubmed: 27076651
BMJ Glob Health. 2019 Sep 24;4(5):e001500
pubmed: 31637024
Arch Public Health. 2021 Feb 4;79(1):17
pubmed: 33541416
Arch Public Health. 2022 May 20;80(1):142
pubmed: 35590340
Int J Public Health. 2014 Jun;59(3):529-39
pubmed: 24647671
Environ Health. 2012 Jun 27;11:42
pubmed: 22715989
BMC Public Health. 2015 Sep 18;15:914
pubmed: 26385563
Am J Clin Nutr. 2015 Mar;101(3):613-21
pubmed: 25733647
Public Health. 2019 Jul;172:22-30
pubmed: 31154234
Eur J Public Health. 2007 Apr;17(2):121
pubmed: 17299007
Eur J Public Health. 2014 Jun;24(3):399-403
pubmed: 24709510
BMC Public Health. 2006 Oct 18;6:255
pubmed: 17049075
PLoS One. 2020 Mar 2;15(3):e0226766
pubmed: 32119685
BMC Public Health. 2020 Sep 17;20(1):1415
pubmed: 32943028
Eur J Public Health. 2017 Feb 1;27(suppl_1):14-21
pubmed: 28355643
BMC Med. 2020 Jan 10;18(1):5
pubmed: 31918762
Lancet. 2014 May 10;383(9929):1655-1664
pubmed: 24522180
Lancet. 2018 May 19;391(10134):2029-2035
pubmed: 29627167
Clin Kidney J. 2020 Nov 30;14(1):1-4
pubmed: 33564399
Rev Panam Salud Publica. 2002 Dec;12(6):398-414
pubmed: 12690727
PLoS One. 2019 Apr 10;14(4):e0214865
pubmed: 30969992
Front Public Health. 2020 Nov 26;8:574111
pubmed: 33324597
Health Syst Transit. 2018 Sep;20(4):1-230
pubmed: 30277214
Lancet Glob Health. 2020 Apr;8(4):e511-e523
pubmed: 32199120
Lancet. 2020 Oct 17;396(10258):1204-1222
pubmed: 33069326
Nat Rev Cardiol. 2022 Feb;19(2):133-143
pubmed: 34497402
Int J Environ Res Public Health. 2013 Sep 17;10(9):4418-31
pubmed: 24048208
Eur J Public Health. 2014 Jun;24(3):357-63
pubmed: 23813717
Soc Sci Med. 2020 Dec;267:113357
pubmed: 32980174